Announcement under Regulation 30 (LODR)-Allotment
Allotment of 2,55,000 equity shares under ESOS21-06-2018
21-06-2018
Receipt Of Establishment Inspection Report (EIR) US FDA -Reg
Receipt of Establishment Inspection Report (EIR) US FDA -Reg01-06-2018
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for IDBI Trusteeship Services Ltd30-05-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Granules Pharmaceuticals, Inc., the wholly owned subsidiary of Granules India Ltd., launched generic Methylergonovine tablets in partnership with Hikma.30-05-2018
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Krishna Prasad Chigurupati30-05-2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of the Investor Meeting28-05-2018
Announcement under Regulation 30 (LODR)-Investor Presentation
Presentation to the Analysts/Investors24-05-2018
Board recommends Final Dividend
Granules India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 24, 2018, inter alia, has recommended to the members, a final dividend of 25 paise per share of face value of Re. 1/- each for the financial year 2017-18 representing 25% of paid-up capital in addition to the interim dividend of 75 paise per share paid during the year.24-05-2018
Board Meeting-Outcome of Board Meeting
Outcome of 185th Board meeting dated 24th May, 201824-05-2018
Results For The Financial Year Ending 31St March 2018.
Results for the Financial Year Ending 31st March 2018.24-05-2018